Tekla Capital Management LLC increased its holdings in shares of The Medicines Company (NASDAQ:MDCO) by 158.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 428,992 shares of the company’s stock after buying an additional 263,151 shares during the period. Tekla Capital Management LLC owned about 0.58% of The Medicines worth $8,211,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in MDCO. Iridian Asset Management LLC CT increased its stake in The Medicines by 75.4% during the 4th quarter. Iridian Asset Management LLC CT now owns 3,296,816 shares of the company’s stock worth $63,101,000 after buying an additional 1,417,229 shares during the period. Westfield Capital Management Co. LP increased its stake in The Medicines by 21.6% during the 4th quarter. Westfield Capital Management Co. LP now owns 4,604,719 shares of the company’s stock worth $88,134,000 after buying an additional 817,508 shares during the period. Oregon Public Employees Retirement Fund purchased a new stake in The Medicines during the 4th quarter worth approximately $25,000. University of Notre Dame DU Lac increased its stake in The Medicines by 248.0% during the 3rd quarter. University of Notre Dame DU Lac now owns 297,859 shares of the company’s stock worth $8,909,000 after buying an additional 212,277 shares during the period. Finally, Federated Investors Inc. PA purchased a new stake in The Medicines during the 3rd quarter worth approximately $6,275,000.
Get The Medicines alerts:
In other news, EVP Christopher T. Cox purchased 113,500 shares of the stock in a transaction on Thursday, December 20th. The stock was bought at an average price of $17.70 per share, for a total transaction of $2,008,950.00. Following the acquisition, the executive vice president now directly owns 60,308 shares of the company’s stock, valued at approximately $1,067,451.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Alexander J. Denner purchased 248,100 shares of the stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $24.91 per share, with a total value of $6,180,171.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 1,675,389 shares of company stock valued at $36,839,238 in the last quarter. 10.29% of the stock is currently owned by company insiders.
NASDAQ MDCO traded up $0.41 on Monday, hitting $25.58. 9,659 shares of the stock were exchanged, compared to its average volume of 1,165,915. The company has a quick ratio of 2.40, a current ratio of 2.41 and a debt-to-equity ratio of 31.23. The Medicines Company has a fifty-two week low of $16.69 and a fifty-two week high of $41.57. The stock has a market capitalization of $1.87 billion, a PE ratio of -8.75 and a beta of 1.18.
The Medicines (NASDAQ:MDCO) last posted its quarterly earnings results on Wednesday, February 27th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.05). The Medicines had a negative return on equity of 1,477.75% and a negative net margin of 668.93%. During the same quarter last year, the firm posted ($0.61) EPS. On average, equities research analysts expect that The Medicines Company will post -1.64 earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on the stock. BidaskClub raised shares of The Medicines from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Zacks Investment Research raised shares of The Medicines from a “sell” rating to a “hold” rating in a research note on Monday, December 31st. Wolfe Research assumed coverage on shares of The Medicines in a research note on Friday, December 14th. They set an “outperform” rating on the stock. Finally, Goldman Sachs Group assumed coverage on shares of The Medicines in a research note on Thursday, December 13th. They set a “neutral” rating and a $25.00 target price on the stock. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The Medicines currently has a consensus rating of “Buy” and a consensus price target of $45.00.
COPYRIGHT VIOLATION WARNING: “Tekla Capital Management LLC Acquires 263,151 Shares of The Medicines Company (MDCO)” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at www.tickerreport.com/banking-finance/4213631/tekla-capital-management-llc-acquires-263151-shares-of-the-medicines-company-mdco.html.
The Medicines Company Profile
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.
Further Reading: What are the components of an earnings report?
Want to see what other hedge funds are holding MDCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Medicines Company (NASDAQ:MDCO).